aspaveli
swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobīnūrija, paroksizmāla - imūnsupresanti - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiski līdzekļi - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multiple mieloma - antineoplastiski līdzekļi - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
enjaymo
sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imūnsupresanti - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psoriāze - imūnsupresanti - treatment of moderate-to-severe plaque psoriasis in adults.
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatas audzējiem, kastrācija-izturīgs - antineoplastiski līdzekļi - treatment of adult patients with prostate cancer.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
litfulo
pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imūnsupresanti - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
jaypirca
eli lilly nederland b.v. - pirtobrutinib - limfoma, mantle-cell - proteīnkināzes inhibitori - treatment of mantle cell lymphoma (mcl).